Cash position of €17.2m as of December 31, 2025 Progresses achieved with our flagship projects in 2025: Chinese partner Tonghua Dongbao completed BioChaperone Lispro Phase 3 program with positive results in people with type 1 and type 2 diabetes in China, and the marketing authorization filling is in preparation Continued development of BioChaperone, with two new feasibility studies in collaboration with two large pharmaceutical companies in the fields of diabetes and obesity Patent application filed for a new long-acting technology platform AdoXLong, with initial positive in vitro and in vivo results generated with semaglutide Continued development of AdoShell platform, with…